Organigram Global Inc. has increased its stake in cannabis genetics leader Phylos Bioscience Inc. by adding a US$3 million advance to its existing loan, bringing the total investment to US$10 million and extending the partnership through 2030.
The new terms grant Organigram priority access to Phylos’ autoflower genetics pipeline and a five‑year exclusivity on selected cultivars in Canada, Australia, the United Kingdom, Germany, and Israel. The loan, which now totals US$10 million, will mature on May 25 2028, and the agreement provides Organigram long‑term rights in international markets, positioning the company to launch differentiated, high‑potency products in key medical and recreational segments.
This investment underpins Organigram’s seed‑based cultivation strategy, which has already delivered higher consistency, yield, and cost efficiency. By securing a pipeline of next‑generation genetics, the company can accelerate product development, protect its market share, and strengthen its competitive moat in both domestic and international cannabis markets. The exclusivity in major markets also supports Organigram’s global expansion plans, aligning with its rebranding to Organigram Global Inc. in March 2025 and its ongoing international sales initiatives.
Organigram’s Q4 Fiscal 2025 results—record gross revenue of US$123.3 million and adjusted EBITDA of US$9.8 million—provide a strong financial backdrop for this commitment. The company’s #1 market share in Canada and robust revenue growth underscore the strategic fit of the Phylos partnership, which is expected to enhance product differentiation and drive future revenue growth.
Borna Zlamalik, SVP Innovation & International R&D, said, “Seed‑based cultivation has become a key advantage of Organigram’s strategy, giving us unprecedented consistency, scalability, and economic benefit. The follow‑on investment in Phylos secures the portfolio breadth of next‑generation cultivars required to meet the needs of our consumers and patients.” Ralph Risch, CEO of Phylos, added, “Organigram saw early that the next phase of cannabis production would be driven by scientifically bred genetics. Their investment allows Phylos to accelerate development of new traits and F1 hybrid seeds, while giving Organigram a meaningful economic advantage as the first to deploy those innovations at commercial scale.”
The long‑term nature of the agreement, coupled with exclusive access to high‑potency genetics, positions Organigram to maintain its leadership in the cannabis market and to capitalize on growing demand for consistent, high‑quality products worldwide. The partnership is expected to reinforce Organigram’s competitive advantage and support its strategic goal of becoming a global leader in seed‑based cannabis cultivation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.